The Central Drugs Standard Control Organisation (CDSCO) has recently flagged over 50 drugs as “not of standard quality” (NSQ). This alarming revelation has significant implications for public health and safety. Here are the key points you need to know:
- Scope of the Issue: The CDSCO identified over 50 drugs, including widely used medications like Paracetamol and Pantoprazole, as sub-standard.
- Types of Medications Affected: The list includes a variety of drugs such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.
- Specific Drugs Highlighted: Notable mentions include Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd, and calcium and vitamin D3 tablets from Pure & Cure Healthcare Pvt. Ltd.
- Geographical Spread: The sub-standard drugs were produced in various regions, including Himachal Pradesh, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore.
- Pharmaceutical Companies Involved: Companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and Meg Lifesciences were among those flagged.
- Industry Response: Some pharmaceutical companies have denied responsibility, claiming that the flagged drugs are spurious and not manufactured by them.
- Regulatory Actions: The CDSCO conducts monthly random sampling to ensure drug quality, and this report is part of their ongoing efforts to maintain high standards.
- Public Health Concerns: The failure of commonly used drugs like Paracetamol to meet quality standards raises significant public health concerns, especially for medications used for pain and fever relief.
- Historical Context: This is not the first time the CDSCO has flagged sub-standard drugs. Previous reports have also highlighted similar issues, indicating a persistent problem in the pharmaceutical industry.
- Consumer Awareness: It is crucial for consumers to stay informed about the quality of medications they use and to report any adverse effects to healthcare providers immediately.
-
Best Large & Mid Cap Funds for May 2026: Which of These 6 Funds Deserves a Spot in Your Portfolio Right Now?
Every serious equity investor in India eventually arrives at the same crossroads — do you go all-in on
-
Motilal Oswal Contra Fund NFO Opens May 8 — Is Contrarian Investing the Smartest Bet in Today’s Uncertain Market?
When everyone is running away from the fire, the contrarian investor is quietly studying which assets are worth
-
Top 5 Pharma Mutual Funds of 2026: One Fund Delivered 28.61% in 3 Years — Did You Miss the Healthcare Rally?
Healthcare is no longer just a defensive sector. In 2026, it has become one of the most compelling
-
The 50-30-20 Rule for Mutual Funds: Why Experts Say This Simple Formula Could Outsmart Most Seasoned Investors
There is a quiet revolution happening in personal finance, and it does not involve exotic derivatives, algorithmic trading,
-
Invesco Reopens 3 International Funds — Is Now the Right Time to Add Global Exposure to Your SIP Portfolio?
If you have been waiting for a window to diversify your mutual fund portfolio beyond Indian borders, that
-
Union MF’s Arthaya SIF Is Live: Can a Long-Short Equity Fund Actually Protect Your Money When Markets Crash?
Union MF just launched India’s first long-short equity SIF — Arthaya. It can profit even when markets crash.





